Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Rhea-AI Summary

Psyence Biomedical (Nasdaq: PBM), a developer of nature-derived psilocybin-based therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9th-11th, 2024 at the Lotte New York Palace Hotel in New York City.

Key points:

• Psyence Biomed will present virtually and engage in one-on-one investor meetings
• The company's corporate presentation will be available on-demand from September 9th at 7:00 am (ET)
• Interested parties can schedule meetings with management by emailing ir@psyencebiomed.com

This participation provides an opportunity for Psyence Biomed to showcase its developments in psilocybin-based therapeutics to a global investment audience.

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of nature-derived psilocybin-based therapeutics, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024 in New York.

Psyence Biomed’s corporate presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform.

If you would like to schedule a meeting with management, please reach out to Psyence Biomed directly via email: ir@psyencebiomed.com.

About Psyence Biomedical

Psyence Biomedical Ltd. (Nasdaq: PBM) is the world’s first life science biotechnology company focused on the development of botanical (nature-derived, or non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence is initially focused on mental health disorders in the context of Palliative Care.

Learn more at www.psyencebiomed.com and on LinkedIn.

Contact Information

Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708

Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com

FAQ

When and where is Psyence Biomed (PBM) presenting at the H.C. Wainwright Global Investment Conference?

Psyence Biomed (PBM) will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9th-11th, 2024 at the Lotte New York Palace Hotel in New York City.

How can investors access Psyence Biomed's (PBM) corporate presentation at the conference?

Psyence Biomed's (PBM) corporate presentation will be available on-demand beginning on Monday, September 9th at 7:00 am (ET) via the conference platform.

What is the focus of Psyence Biomed's (PBM) research and development?

Psyence Biomed (PBM) is a developer of nature-derived psilocybin-based therapeutics.

How can investors schedule meetings with Psyence Biomed (PBM) management during the conference?

Investors can schedule meetings with Psyence Biomed (PBM) management by emailing ir@psyencebiomed.com directly.